

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**華潤醫藥集團有限公司**

**China Resources Pharmaceutical Group Limited**

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

## ANNUAL GENERAL MEETING HELD ON 29 MAY 2023 POLL RESULTS

The Company is pleased to announce that all the resolutions set out in the notice of AGM and proposed at the AGM were duly passed by the shareholders of the Company by way of poll at the AGM.

China Resources Pharmaceutical Group Limited (the “**Company**”) is pleased to announce the poll results in respect of the resolutions proposed at the annual general meeting of the Company held on 29 May 2023 (the “**AGM**”) as follows:

Ordinary Resolutions proposed at the AGM		Number of Votes (%)	
		For	Against
1.	To receive and consider the audited financial statements, the directors’ report and the independent auditor’s report of the Company for the year ended 31 December 2022.	5,347,063,433 (99.93%)	3,707,600 (0.07%)
The resolution was duly passed as an ordinary resolution.			
2.	To declare a final dividend of HK\$0.16 per share for the year ended 31 December 2022.	5,350,771,033 (100%)	0 (0.00%)
The resolution was duly passed as an ordinary resolution.			
3.	(1) To re-elect Mdm. Guo Wei as Director.	5,272,691,760 (98.54%)	78,079,273 (1.46%)
The resolution was duly passed as an ordinary resolution.			
	(2) To re-elect Mr. Han Yuewei as Director.	5,193,486,637 (97.06%)	157,284,396 (2.94%)
The resolution was duly passed as an ordinary resolution.			
	(3) To re-elect Mr. Hou Bo as Director.	5,272,413,760 (98.54%)	78,357,273 (1.46%)
The resolution was duly passed as an ordinary resolution.			

Ordinary Resolutions proposed at the AGM		Number of Votes (%)	
		For	Against
(4)	To re-elect Mr. Fu Tingmei as Director.	5,336,222,129 (99.73%)	14,548,904 (0.27%)
The resolution was duly passed as an ordinary resolution.			
(5)	To re-elect Mr. Zhang Kejian as Director.	5,342,186,629 (99.84%)	8,584,404 (0.16%)
The resolution was duly passed as an ordinary resolution.			
(6)	To authorise the Board to fix the remuneration of the Directors.	5,350,261,791 (99.99%)	449,742 (0.01%)
The resolution was duly passed as an ordinary resolution.			
4.	To appoint KPMG as the auditor of the Company and to authorise the Board to fix their remuneration.	5,348,066,533 (99.95%)	2,704,500 (0.05%)
The resolution was duly passed as an ordinary resolution.			
5.	Ordinary Resolution in item No.5 of the Notice of Annual General Meeting (To give a general mandate to the Directors to buy back shares of the Company).	5,303,597,033 (99.12%)	47,174,000 (0.88%)
The resolution was duly passed as an ordinary resolution.			
6.	Ordinary Resolution in item No.6 of the Notice of Annual General Meeting (To give a general mandate to the Directors to issue new shares of the Company).	4,862,530,546 (90.88%)	488,240,487 (9.12%)
The resolution was duly passed as an ordinary resolution.			
7.	Ordinary Resolution in item No. 7 of the Notice of Annual General Meeting (To extend the general mandate to be given to the Directors to issue new shares of the Company).	4,870,326,546 (91.02%)	480,444,487 (8.98%)
The resolution was duly passed as an ordinary resolution.			

As at the date of the AGM, the total number of issued and fully paid up shares of the Company was 6,282,510,461 shares. In relation to all resolutions proposed at the AGM, the total number of shares entitling the holders to attend and vote for or against the resolutions at the AGM was 6,282,510,461 shares. There were no shares entitling the holders to attend and abstain from voting in favour of the resolutions at the AGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and there were no shares requiring the holders to abstain from voting at the AGM under the Listing Rules. No shareholders of the Company have stated their intention in the circular of the Company dated 27 April 2023 (the “**Circular**”) to vote against or to abstain from voting on any of the proposed resolutions at the AGM.

Mr. Tao Ran, the director of the Company, presided the AGM. The directors Mr. Lin Guolong, Mdm. Guo Wei, Mr. Hou Bo, Mdm. Jiao Ruifang, Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian attended the AGM in person or via video conference, whilst Mr. Han Yuewei, Mr. Bai Xiaosong and Mdm. Weng Jingwen, were unable to attend the AGM due to other business commitments.

Tricor Investor Services Limited, the share registrar of the Company, acted as scrutineers for the vote-taking at the AGM.

Shareholders may refer to the Circular for details of the above resolutions proposed at the AGM. The Circular may be viewed and downloaded from the Company's website at [www.crpharm.com](http://www.crpharm.com) or the website of The Stock Exchange of Hong Kong Limited at [www.hkexnews.hk](http://www.hkexnews.hk).

For and on behalf of  
**China Resources Pharmaceutical Group Limited**  
**Han Yuewei**  
*Chairman*

Beijing, 29 May 2023

*As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mr. Tao Ran and Mdm. Weng Jingwen as executive Directors, Mr. Lin Guolong, Mdm. Guo Wei, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.*